Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow
Information source: Mashhad University of Medical Sciences
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Slow Coronary Flow; Normal, or Near Normal Coronary Angiography; Stable Angina
Intervention: Nicorandil (Drug); Nitroglycerin (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Mashhad University of Medical Sciences
Summary
Slow coronary flow is an angiographically diagnosed phenomenon defined as delayed
opacification of epicardial arteries in the absence of significant arterial narrowing and
blockade. Endothelial dysfunction at the level of microarteries have been proposed as the
main pathological mechanism in this regard. Available evidence suggest that standard
anti-angina medications (e. g. nitroglycerin) that solely target large coronary trunks might
not provide adequate symptomatic relief in patients with slow coronary flow phenomenon. It
is hypothesized that anti-angina medications which exert vasodilatory effects in large
coronary arteries as well as small dividing branches might be superior to nitroglycerin in
amelioration of angina symptoms. The present randomized clinical trial was thus designed and
conducted to compare the short-term efficacy of nicorandil (a dual-acting anti-angina
medication with effects on both large and small coronary vessels) with nitroglycerin in a
group of patients with slow coronary flow presented with frequent angina episodes.
Clinical Details
Official title: Nicorandil Versus Nitroglycerin for Symptomatic Relief of Angina in Patients With Slow Coronary Flow Phenomenon Visited in Imam Reza Hospital, Mashhad, Iran
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: Angina Episode FrequnecyAngina Episode Intensity Canadian Cardiovascular Society (CCS) Grading of Angina Pectoris
Secondary outcome: Side-effects
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- on coronary angiographic studies, arterial narrowing did not exceed 50% in any of the
three main coronary arteries; (
- a delayed opacification in at least one of the main coronary arteries was documented.
Delayed opacification was defines as corrected TIMI frame count > 23 fps
Exclusion Criteria:
- comorbid cardiovascular condition other than mild coronary atherosclerosis and
coronary slow flow
- refusal to participate
- discontinuation of treatment
- not returning for the follow up visit
Locations and Contacts
Additional Information
Starting date: March 2012
Last updated: March 28, 2015
|